|
|
Blood, Vol. 110, Issue 1, 424-432, July 1, 2007
Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy
Blood Buza-Vidas et al.
110: 424
Supplemental materials for: Buza-Vidas et al, Volume 110, Issue 1, 424-432
Files in this Data Supplement:
- Figure S1. Representative FACS plots of cells from 2-week-old WT and FL–/– mice (PDF, 703 KB) -
Representative FACS plots of BM CLP (A: Lin−SCA1loc-KITloIL-7Rα+), pre-pro-B/pro-B (B: B220+CD43+AA4.1+CD19−/ B220+CD43+AA4.1+CD19+), pre-B (C: B220+CD43−IgM−), BM B220+IgM+, and PB B220+IgM+ cells (D) from 2-week-old WT and FL–/– mice, respectively. Numbers represent frequency of indicated population of total BM and PB cells.
- Figure S2. No effect of FLT3 ligand treatment on regeneration of peripheral B cells in FL–/– recipients that were given BM transplants (PDF, 214 KB) -
Lethally irradiated adult FL–/– mice were given transplants of 2 × 105 FL–/– BM cells, and treated with either PBS carrier (control), or 0.4 µg or 10 µg FLT3 ligand. Treatment with control or FLT3 ligand started at the time of transplantation and continued every other day for 3 weeks, at which time PB was harvested and analyzed for B-cell reconstitution. Numbers represent mean (SEM) values from of 2 to 3 mice per group.
|
|
